We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Neuropatía inducida por el tratamiento médico del cáncer.
- Authors
Cardona, Andrés Felipe; Ortiz, León Darío; Reveiz, Ludovic; Becerra, Henry Alberto; Arango, Natalia; Santacruz, Juan Guillermo; Otero, Jorge Miguel; Carranza, Hernán; Ojeda, Kelman; Rojas, Leonardo; Vargas, Carlos Alberto; Rodríguez, Myriam; Castro, Carlos; Camacho, María Isabel; Serrano, Silvia Juliana; Torres, Diana; Balañá, Carmen
- Abstract
Recent advances in the development and administration of therapy for malignant diseases have been rewarded with prolonged survival rates. Unlike more immediate toxicities that affect the gastrointestinal tract and bone marrow, chemotherapy-induced neurotoxicity is frequently delayed in onset and may progress over time. In the peripheral nervous system, the major brunt of the toxicity is directed against the peripheral nerve, resulting in cancer therapy-induced peripheral neuropathy. Chemotherapeutic agents used to treat hematologic and solid tumors target a variety of structures and functions in the peripheral nervous system, including the neuronal cell body, the axonal transport system, the myelin sheath, and glial support structures. Each agent exhibits a spectrum of effects unique to its mechanism of action, and recent studies in this field have yielded clearer ideas on how to mitigate injury. Combined with the call for a greater recognition of the devastating effects of cancer therapy-induced peripheral neuropathy on quality of life, basic and clinical researchers have begun to investigate therapy to prevent and treat neurologic damage. This review was made based on relevant information avaliable on international databases concerning cancer therapy-induced peripheral neuropathy and summarizes the evidence for diagnosis, pharmacologic and nonpharmacologic approaches to the management of this commonly unrecognized condition. In conclusion, the information avaliable in this moment establish the mechanisms of the disease and exposes the importance of the development of statistically stronger clinical trials that complement current data available in this moment.
- Subjects
DISEASES; TOXICITY testing; BONE marrow; DRUG therapy; MATHEMATICAL functions; CANCER treatment
- Publication
Médicas UIS, 2010, Vol 23, Issue 2, p100
- ISSN
0121-0319
- Publication type
Article